All The Secrets About Amazing New Quit Smoking Pills
Big pharmaceutical companies from all over the world have entered a close race to find the wonder new quit smoking pill, that could make nicotine addiction as treatable as acid ulcer, high blood pressure or erectile dysfunctions.
Very popular and supposedly efficient quit smoking pills are some anti-depressives. Paradoxically, smokers suffering from depression who were taking Bupropion realized that while under medication they showed no desire to smoke. This is how the fame of Bupropion, also known as Zyban is made.
This new quit smoking pill is nicotine free, it gives no addiction, and its efficiency shows in the smoker's increased capacity of fighting cessation symptoms. Zyban acts on the brain to nullify your craving for nicotine. This mild anti-depressant works best in association with nicotine chewing gum and patches.
Zyban is a quit smoking pill that should be administered twice a day with or without food, and it should be taken whole, no crushing allowed since it diminishes its effect. It is not recommended to teenagers under eighteen or to people suffering from epilepsy.
Zyban is to be administrated only under doctor's observance. Though a very advanced new quit smoking pill, it still has some side effects, like headaches, stomachaches, dizziness and even increased blood pressure when used in association with nicotine patches.
Another very effective new quit smoking pill is Varenicline Tartrate, a drug that works differently from the other nicotine based quit smoking pills. It acts at the brain level directly on the nicotine receptors. Basically it competes with nicotine at the receptive site in the brain.
Veranicline has also the advantage of depriving the person of the smoking satisfaction. When under treatment with this new quit smoking pill, the smoker feels no pleasure in smoking. The condition to administrate Veranicline is to have been smoking for at least a year.
Another new quit smoking pill meant to disrupt the nicotine vicious circuit is Acomplia, produced by the French Pharmaceutical company Sanofi-Synthelabo. Nicotine addiction functions on the reward the body receives when the person lights up. Acomplia targets precisely the blockage of this reward system, which will make smoking dissatisfying.
The most probable of results is that doctors will keep inventing new quit smoking pills, but none will be able to cure nicotine addiction 100 percent. With the release of a new quit smoking pill there are always high expectations, and there are people who really quit, but this very much depends on personal effort as well.
No new quit smoking pill can cure the two sides of an addiction, the physical and the psychological. For psychological healing alternative therapies and counseling will offer the necessary support.